HF
AKTX

HRT Financial’s Akari Therapeutics AKTX Stock Holding History

HRT Financial’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-24
Closed -$31K – 3105
2021
Q3 		$31K Sell
24
-3
-11% -$4.08K ﹤0.01% 3105
2021
Q2 		$37K Buy
27
+7
+35% +$11.2K ﹤0.01% 2697
2021
Q1 		$42K Buy
+20
New +$45.3K ﹤0.01% 2557
2020
Q4 		– Sell
-63
Closed -$88K – 1795
2020
Q3 		$88K Buy
63
+48
+320% +$71.2K ﹤0.01% 1562
2020
Q2 		$26K Buy
+15
New +$22.9K ﹤0.01% 1380

Other funds holding AKTX

OFW
Omnia Family Wealth Aventura, Florida $373M AUM 25.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BMCM
Bryn Mawr Capital Management Philadelphia, Pennsylvania $2.06B AUM 19.82% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CAN
Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

HRT Financial's AKTX Position: Q4 2021 in Review

HRT Financial sold out of Akari Therapeutics (AKTX) in Q4 2021, closing a stake of 24 shares — an estimated $31K sold.

HRT Financial first reported a position in AKTX in Q2 2020 and held it in 5 quarters. The position peaked at $88K in Q3 2020. 11 funds tracked by Wall St. Rank hold AKTX as of Q4 2021.

  • HRT Financial reported no remaining Akari Therapeutics position as of Q4 2021 after selling out during the quarter.
  • HRT Financial sold 24 Akari Therapeutics shares in Q4 2021, an estimated $31K.
  • HRT Financial first reported a position in Akari Therapeutics in Q2 2020 and held it in 5 quarters.
  • HRT Financial's Akari Therapeutics position peaked at $88K in Q3 2020.
  • 11 funds tracked by Wall St. Rank held Akari Therapeutics as of Q4 2021.

Based on HRT Financial's 13F filing for Q4 2021, filed 14 Feb 2022.